AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)
A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA).
Sponsor: AstraZeneca
A PHASE3 clinical study on Stage IB-IIIA Non-small Cell Lung Carcinoma, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 45 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
45 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 40 earlier versions
-
Jan 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Apr 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Arkhangelsk, Russia , Arnhem, Netherlands , Athens, United States , Bangkok, Thailand , Barcelona, Spain , Bari, Italy and 183 more locations